Avalyn Pharma develops inhaled formulations of anti‑fibrotic drugs, such as pirfenidone (AP01), delivered via a handheld eFlow® nebulizer that targets the lung directly. This lung‑focused delivery enables lower systemic doses, reducing side effects and improving patient adherence while aiming to stabilize lung function in progressive interstitial lung diseases.

Immusoft utilizes Immune System Programming (ISP™) to reprogram a patient's B cells into plasma cells that produce therapeutic proteins, effectively creating personalized biofactories for treatment. This technology addresses the need for sustained delivery of gene-encoded medicines for rare diseases, offering long-term therapeutic benefits from the patient's own cells.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

Oncternal Therapeutics is a clinical-stage oncology company developing targeted therapies for hematological malignancies and prostate cancer by exploring untapped biological pathways involved in cancer progression. The company addresses the critical unmet medical needs of patients with these cancers through its diverse pipeline of treatment modalities.

SelectION is a clinical-stage biopharmaceutical company developing therapeutic peptides that selectively target ion channels, specifically Kv1.3, to treat autoimmune diseases such as psoriasis and psoriatic arthritis. Their lead asset, si-544, offers a short treatment course with a favorable safety profile while maintaining patients' full immunocompetence, thereby improving quality of life for those affected by T cell autoimmunity.

VelosBio develops novel antibody-drug conjugates specifically targeting hematological cancers, utilizing a precise mechanism to deliver cytotoxic agents directly to cancer cells. This approach aims to improve treatment efficacy while minimizing systemic toxicity associated with traditional chemotherapy.